Free Trial

Anavex Life Sciences (AVXL) Competitors

$3.70
-0.05 (-1.33%)
(As of 12:04 PM ET)

AVXL vs. BASI, CGEM, FDMT, TARS, AUTL, DNA, IMTX, RLAY, PRME, and HUMA

Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Bioanalytical Systems (BASI), Cullinan Therapeutics (CGEM), 4D Molecular Therapeutics (FDMT), Tarsus Pharmaceuticals (TARS), Autolus Therapeutics (AUTL), Ginkgo Bioworks (DNA), Immatics (IMTX), Relay Therapeutics (RLAY), Prime Medicine (PRME), and Humacyte (HUMA). These companies are all part of the "medical" sector.

Anavex Life Sciences vs.

Anavex Life Sciences (NASDAQ:AVXL) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Anavex Life Sciences currently has a consensus target price of $40.00, suggesting a potential upside of 966.67%. Given Anavex Life Sciences' higher probable upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Bioanalytical Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bioanalytical Systems
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 11.5% of Bioanalytical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anavex Life Sciences has a net margin of 0.00% compared to Bioanalytical Systems' net margin of -7.75%. Anavex Life Sciences' return on equity of -29.04% beat Bioanalytical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -29.04% -26.85%
Bioanalytical Systems -7.75%-42.74%-6.38%

Anavex Life Sciences received 297 more outperform votes than Bioanalytical Systems when rated by MarketBeat users. Likewise, 74.17% of users gave Anavex Life Sciences an outperform vote while only 41.03% of users gave Bioanalytical Systems an outperform vote.

CompanyUnderperformOutperform
Anavex Life SciencesOutperform Votes
425
74.17%
Underperform Votes
148
25.83%
Bioanalytical SystemsOutperform Votes
128
41.03%
Underperform Votes
184
58.97%

Anavex Life Sciences has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

In the previous week, Anavex Life Sciences had 6 more articles in the media than Bioanalytical Systems. MarketBeat recorded 6 mentions for Anavex Life Sciences and 0 mentions for Bioanalytical Systems. Anavex Life Sciences' average media sentiment score of 1.05 beat Bioanalytical Systems' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Anavex Life Sciences Positive
Bioanalytical Systems Neutral

Bioanalytical Systems has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Bioanalytical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$47.51M-$0.50-7.50
Bioanalytical Systems$60.47M0.32-$4.68M-$0.35-4.91

Summary

Anavex Life Sciences beats Bioanalytical Systems on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVXL vs. The Competition

MetricAnavex Life SciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$317.40M$2.88B$5.29B$8.38B
Dividend YieldN/A2.28%2.80%4.06%
P/E Ratio-7.5027.64181.7318.40
Price / SalesN/A307.552,286.4479.55
Price / CashN/A158.1933.9530.83
Price / Book2.174.444.944.32
Net Income-$47.51M-$46.09M$109.83M$215.94M
7 Day Performance-6.95%0.74%-0.13%-0.06%
1 Month Performance-6.02%-2.04%0.47%0.03%
1 Year Performance-57.53%-2.15%1.14%2.89%

Anavex Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BASI
Bioanalytical Systems
0 of 5 stars
$1.72
-3.4%
N/A-68.4%$19.15M$60.47M-4.10397Analyst Forecast
Gap Up
High Trading Volume
CGEM
Cullinan Therapeutics
2.1235 of 5 stars
$21.71
-6.6%
$32.00
+47.4%
+70.8%$1.25B$18.94M-6.9485Short Interest ↑
FDMT
4D Molecular Therapeutics
2.3685 of 5 stars
$24.07
+3.3%
$45.63
+89.6%
+4.9%$1.24B$20.72M-9.86147Gap Up
TARS
Tarsus Pharmaceuticals
1.4773 of 5 stars
$32.74
+0.4%
$50.38
+53.9%
+79.2%$1.24B$17.45M-6.86244Gap Up
AUTL
Autolus Therapeutics
2.4674 of 5 stars
$4.34
+0.7%
$8.70
+100.5%
+52.3%$1.15B$10.50M-3.62463Short Interest ↑
Gap Up
DNA
Ginkgo Bioworks
2.3775 of 5 stars
$0.51
-1.9%
$1.90
+275.3%
-74.1%$1.12B$251.46M-1.151,218Short Interest ↓
Gap Up
IMTX
Immatics
0.531 of 5 stars
$13.12
-1.1%
$16.00
+22.0%
+16.2%$1.11B$58.44M-12.38432Short Interest ↑
Positive News
Gap Up
RLAY
Relay Therapeutics
2.0075 of 5 stars
$7.84
+8.4%
$22.80
+190.8%
-30.9%$1.04B$25.55M-2.97323Short Interest ↓
Analyst Revision
PRME
Prime Medicine
3.4999 of 5 stars
$7.68
+3.5%
$15.09
+96.5%
-47.8%$921.83MN/A-3.54234Gap Up
HUMA
Humacyte
0.8109 of 5 stars
$7.34
+5.0%
$8.00
+9.0%
+87.2%$874.05M$1.57M-7.34183Short Interest ↑
Gap Up

Related Companies and Tools

This page (NASDAQ:AVXL) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners